{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:07Z","timestamp":1783723447127,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Betahistine is a clinical medication for the treatment of benign paroxysmal positional vertigo (BPPV). Otolin, a secreted glycoprotein with a C-terminal globular domain homologous to the immune complement C1q, has been identified as a biomarker for BPPV. However, the role of complement C1q\/TNF-related proteins (CTRPs) with a C-terminal globular domain in BPPV is unclear, so we explored the change of CTRPs in betahistine treated BPPV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We treated BPPV patients with Betahistine (12\u00a0mg\/time, 3 times\/day) for 4\u00a0weeks and observed the clinical efficacy and the expression of CTRP family members in BPPV patients. Then, we constructed a vertigo mice model of vestibular dysfunction with gentamicin (150\u00a0mg\/Kg) and a BPPV model of <jats:italic>Slc26a4<\/jats:italic><jats:sup><jats:italic>loop\/loop<\/jats:italic><\/jats:sup> mutant mice. Adenoviral vectors for CTRP expression vector and small interfering RNA were injected via the intratympanic injection into mice and detected the expression of CTRP family members, phosphorylation levels of ERK and AKT and the expression of PPAR\u03b3. In addition, we treated mice of vestibular dysfunction with Betahistine (10\u00a0mg\/Kg) and\/or ERK inhibitor of SCH772984 (12\u00a0mg\/Kg) and\/or and PPAR\u03b3 antagonist GW9662 (1\u00a0mg\/Kg) for 15\u00a0days, and evaluated the accuracy of air righting reflex, the time of contact righting reflex and the scores of head tilt and swimming behavior.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After treatment with Betahistine, the residual dizziness duration and the score of the evaluation were reduced, and the expression of CTRP1, 3, 6, 9 and 12 were significantly increased in BPPV patients. We also found that Betahistine improved the accuracy of air righting reflex, reduced the time of contact righting reflex and the scores of head tilt and swimming behavior in gentamicin-treated mice and <jats:italic>Slc26a4<\/jats:italic><jats:sup><jats:italic>loop\/loop<\/jats:italic><\/jats:sup> mutant mice. The expression levels of CTRP1, 3, 6, 9 and 12, phosphorylation levels of ERK and AKT, and PPAR\u03b3 expression were significantly increased, and the scores of head tilt and swimming behavior were decreased in vestibular dysfunction mice with overexpression of CTRPs. Silencing CTRPs has the opposite effect. SCH772984 reversed the effect of Betahistine in mice with vestibular dysfunction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Betahistine alleviates BPPV through inducing production of multiple CTRP family members and activating the ERK1\/2-AKT\/PPARy pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40659-022-00385-3","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:02:45Z","timestamp":1649080965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1\/2-AKT\/PPARy pathway"],"prefix":"10.1186","volume":"55","author":[{"given":"Jing","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-4020","authenticated-orcid":false,"given":"Dingjing","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"issue":"3","key":"385_CR1","first-page":"2412","volume":"41","author":"Y Lou","year":"2020","unstructured":"Lou Y, Cai M, Xu L, Wang Y, Zhuang L, Liu X. Efficacy of BPPV diagnosis and treatment system for benign paroxysmal positional vertigo. Am J Otolaryngol. 2020;41(3):2412.","journal-title":"Am J Otolaryngol"},{"key":"385_CR2","first-page":"67","volume":"82","author":"P Instrum","year":"2019","unstructured":"Instrum P. Benign paroxysmal positional vertigo. Adv Otorhinolaryngol. 2019;82:67\u201376.","journal-title":"Adv Otorhinolaryngol"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cnp.2019.03.001","volume":"4","author":"EC Argaet","year":"2019","unstructured":"Argaet EC, Bradshaw AP, Welgampola MS. Benign positional vertigo, its diagnosis, treatment and mimics. Clin Neurophysiol Pract. 2019;4:97\u2013111.","journal-title":"Clin Neurophysiol Pract"},{"issue":"3_suppl","key":"385_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599816689667","volume":"156","author":"N Bhattacharyya","year":"2017","unstructured":"Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, Holmberg JM, Mahoney K, Hollingsworth DB, Roberts R, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156(3_suppl):S1\u201347.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"12","key":"385_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1017\/S0022215118002037","volume":"132","author":"J Kelkar","year":"2018","unstructured":"Kelkar J. A novel use of intratympanic dexamethasone for intractable posterior canal benign paroxysmal positional vertigo: report of two cases. J Laryngol Otol. 2018;132(12):1147\u20139.","journal-title":"J Laryngol Otol"},{"issue":"3","key":"385_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00016489.2011.637179","volume":"132","author":"HJ Jung","year":"2012","unstructured":"Jung HJ, Koo JW, Kim CS, Kim JS, Song JJ. Anxiolytics reduce residual dizziness after successful canalith repositioning maneuvers in benign paroxysmal positional vertigo. Acta Otolaryngol. 2012;132(3):277\u201384.","journal-title":"Acta Otolaryngol"},{"issue":"6","key":"385_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.amjoto.2014.07.001","volume":"35","author":"Y Deng","year":"2014","unstructured":"Deng Y, Xiong Fu, Lai H. Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. Am J Otolaryngol. 2014;35(6):753\u20137.","journal-title":"Am J Otolaryngol"},{"issue":"Suppl 2","key":"385_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s12070-018-1255-1","volume":"71","author":"L Panuganti","year":"2019","unstructured":"Panuganti L, Tati P. Comparative study of management of BPPV (Benign Paroxysmal Positional Vertigo) with only drugs versus drugs plus epley manoeuvre. Indian J Otolaryngol Head Neck Surg. 2019;71(Suppl 2):1183\u20136.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"385_CR9","first-page":"CD010696","volume":"6","author":"L Murdin","year":"2016","unstructured":"Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016;6:CD010696.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"385_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.14639\/0392-100X-2035","volume":"38","author":"AP Casani","year":"2018","unstructured":"Consensus Conference Group, Casani AP, Guidetti G, Schoenhuber R. Report from a consensus on the treatment of Meniere\u2019s disease with betahistine rationale methodology and results. Acta Otorhinolaryngol Ital. 2018;38(5):460\u20137.","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"3","key":"385_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3892\/etm.2016.3004","volume":"11","author":"C Chen","year":"2016","unstructured":"Chen C, Zhang Li, Zhang K, Lan Wu. Puerarin and betahistine treatment of vertebrobasilar ischemia vertigo: a meta-analysis of randomized controlled trials. Exp Ther Med. 2016;11(3):1051\u20138.","journal-title":"Exp Ther Med"},{"issue":"9","key":"385_CR12","first-page":"936","volume":"38","author":"Jiang Li","year":"2018","unstructured":"Li Jiang. Needle-knife therapy combined with moxa stick pressure moxibustion for cervical vertigo: a randomized controlled trial. Zhongguo Zhen Jiu. 2018;38(9):936\u20139.","journal-title":"Zhongguo Zhen Jiu"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.2147\/NDT.S182809","volume":"14","author":"TJ Wan","year":"2018","unstructured":"Wan TJ, Yu YC, Zhao XG, Tang P, Gong YS. Efficacy of betahistine plus cognitive behavioral therapy on residual dizziness after successful canalith repositioning procedure for benign paroxysmal positional vertigo. Neuropsychiatr Dis Treat. 2018;14:2965\u201371.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"385_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bbrc.2016.11.102","volume":"482","author":"L Chi","year":"2017","unstructured":"Chi L, Hu X, Zhang W, Bai T, Zhang L, Zeng H, Guo R, Zhang Y, Tian H. Adipokine CTRP6 improves PPARgamma activation to alleviate angiotensin II-induced hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats. Biochem Biophys Res Commun. 2017;482(4):727\u201334.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1 2","key":"385_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mce.2013.01.002","volume":"369","author":"H Akiyama","year":"2013","unstructured":"Akiyama H, Otani M, Sato S, Toyosawa S, Furukawa S, Wakisaka S, Maeda T. A novel adipokine C1q\/TNF-related protein 1 (CTRP1) regulates chondrocyte proliferation and maturation through the ERK1\/2 signaling pathway. Mol Cell Endocrinol. 2013;369(1 2):63\u201371.","journal-title":"Mol Cell Endocrinol"},{"key":"385_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13274","author":"H Xiang","year":"2020","unstructured":"Xiang H, Xue W, Li Y, Zheng J, Ding C, Dou M, Wu X. C1q\/TNF-related protein 6 (CTRP6) attenuates renal ischaemia-reperfusion injury through the activation of PI3K\/Akt signalling pathway. Clin Exp Pharmacol Physiol. 2020. https:\/\/doi.org\/10.1111\/1440-1681.13274.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"385_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MAO.0000000000002890","volume":"42","author":"MK Graham","year":"2021","unstructured":"Graham MK, Staab JP, Lohse CM, McCaslin DL. A comparison of dizziness handicap inventory scores by categories of vestibular diagnoses. Otol Neurotol. 2021;42(1):129\u201336.","journal-title":"Otol Neurotol"},{"issue":"4","key":"385_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/archotol.1990.01870040046011","volume":"116","author":"GP Jacobson","year":"1990","unstructured":"Jacobson GP, Newman CW. The development of the dizziness handicap inventory. Arch Otolaryngol Head Neck Surg. 1990;116(4):424\u20137.","journal-title":"Arch Otolaryngol Head Neck Surg."},{"issue":"2","key":"385_CR19","first-page":"179","volume":"69","author":"E Zamys\u0142owska-Szmytke","year":"2018","unstructured":"Zamys\u0142owska-Szmytke E, Szostek-Rogula S, \u015aliwi\u0144ska-Kowalska M. Functional assessment of patients with vertigo and dizziness in occupational medicine. Medycyna Pracy. 2018;69(2):179\u201389.","journal-title":"Medycyna Pracy"},{"issue":"2","key":"385_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2522\/ptj.20120171","volume":"93","author":"F Godi","year":"2013","unstructured":"Godi F, Caligari G, Turcato N. Comparison of reliability, validity, and responsiveness of the mini-BESTest and Berg Balance Scale in patients with balance disorders. Phys Ther. 2013;93(2):158\u201367.","journal-title":"Phys Ther"},{"issue":"5","key":"385_CR21","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1111\/gbb.12635","volume":"19","author":"AA Dror","year":"2020","unstructured":"Dror AA, Taiber S, Sela E, Handzel O, Avraham KB. A mouse model for benign paroxysmal positional vertigo with genetic predisposition for displaced otoconia. Genes, Brain, Behavior. 2020;19(5):2635.","journal-title":"Genes, Brain, Behavior."},{"issue":"2","key":"385_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/72793","volume":"24","author":"MC Simmler","year":"2000","unstructured":"Simmler MC, Cohen-Salmon M, El-Amraoui A, Guillaud L, Benichou JC, Petit C, Panthier JJ. Targeted disruption of otog results in deafness and severe imbalance. Nat Gen. 2000;24(2):139\u201343.","journal-title":"Nat Gen"},{"key":"385_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neures.2017.07.005","volume":"129","author":"T Kawashima","year":"2018","unstructured":"Kawashima T. The role of the serotonergic system in motor control. Neurosci Res. 2018;129:32\u20139.","journal-title":"Neurosci Res"},{"issue":"2","key":"385_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.brainresrev.2003.10.004","volume":"44","author":"N Schweighofer","year":"2004","unstructured":"Schweighofer N, Doya K, Kuroda S. Cerebellar aminergic neuromodulation: towards a functional understanding. Brain Res Brain Res Rev. 2004;44(2):103\u201316.","journal-title":"Brain Res Brain Res Rev"},{"key":"385_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbr.2018.06.012","volume":"359","author":"G-G Manes","year":"2019","unstructured":"Manes G-G, Sandini Z-M, Florio A-R, Wadt B, Massironi M. Behavioral and neurochemical characterization of the mlh mutant mice lacking otoconia. Behav Brain Res. 2019;359:958\u201366.","journal-title":"Behav Brain Res"},{"issue":"3","key":"385_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2004.05.052","volume":"127","author":"C Khan","year":"2004","unstructured":"Khan C, Park L, Lasker J. Abnormal motor behavior and vestibular dysfunction in the stargazer mouse mutant. Neuroscience. 2004;127(3):785\u201396.","journal-title":"Neuroscience"},{"issue":"6","key":"385_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10162-019-00730-6","volume":"20","author":"B Martins-Lopes","year":"2019","unstructured":"Martins-Lopes B, Greguske M, Boadas-Vaello L. Quantitative assessment of anti-gravity reflexes to evaluate vestibular dysfunction in rats. J Assoc Res Otolaryngol. 2019;20(6):553\u201363.","journal-title":"J Assoc Res Otolaryngol"},{"issue":"4","key":"385_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tem.2011.12.003","volume":"23","author":"B Schaffler","year":"2012","unstructured":"Schaffler B. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. 2012;23(4):194\u2013204.","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"385_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11154-013-9255-7","volume":"15","author":"MM Seldin","year":"2014","unstructured":"Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord. 2014;15(2):111\u201323.","journal-title":"Rev Endocr Metab Disord"},{"key":"385_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000002621","author":"V Perez-Guillen","year":"2020","unstructured":"Perez-Guillen V, Franco-Gutierrez V, Gil-Aguilar MT, Zamora EG, Perez-Vazquez P. Can benign paroxysmal positional vertigo be treated in a one session? Otol Neurotol. 2020. https:\/\/doi.org\/10.1097\/MAO.0000000000002621.","journal-title":"Otol Neurotol"},{"issue":"3","key":"385_CR31","doi-asserted-by":"publisher","first-page":"e0174114","DOI":"10.1371\/journal.pone.0174114","volume":"12","author":"VA Parfenov","year":"2017","unstructured":"Parfenov VA, Golyk VA, Matsnev EI, Morozova SV, Melnikov OA, Antonenko LM, Sigaleva EE, Situkho MI, Asaulenko OI, Popovych VI, et al. Effectiveness of betahistine (48 mg\/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. PloS ONE. 2017;12(3):e0174114.","journal-title":"PloS ONE"},{"issue":"4","key":"385_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5152\/tao.2019.4185","volume":"57","author":"K Inan","year":"2019","unstructured":"Inan K. An evaluation of the effects of betahistine and dimenhydrinate on posterior canal benign paroxysmal positional vertigo. Turk Arch Otorhinolaryngol. 2019;57(4):191\u20136.","journal-title":"Turk Arch Otorhinolaryngol"},{"issue":"1","key":"385_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119\u201326.","journal-title":"Curr Pharm Des"},{"key":"385_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fneur.2020.00367","volume":"11","author":"Y Wu","year":"2020","unstructured":"Wu Y, Han W, Yan W, Lu X, Zhou M, Li L, Guan Q, Fan Z. Increased Otolin-1 in serum as a potential biomarker for idiopathic benign paroxysmal positional vertigo episodes. Front Neurol. 2020;11:367.","journal-title":"Front Neurol"},{"issue":"7","key":"385_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1017\/S0022215121001274","volume":"135","author":"DVK Irugu","year":"2021","unstructured":"Irugu DVK, Singh A, Yadav H, Verma H, Kumar R, Abraham RA, Ramakrishnan L. Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study. J Laryngol Otol. 2021;135(7):589\u201392.","journal-title":"J Laryngol Otol"},{"issue":"9","key":"385_CR36","doi-asserted-by":"publisher","first-page":"e12765","DOI":"10.1371\/journal.pone.0012765","volume":"5","author":"MR Deans","year":"2010","unstructured":"Deans MR, Peterson JM, Wong GW. Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1. PloS ONE. 2010;5(9):e12765.","journal-title":"PloS ONE"},{"issue":"3","key":"385_CR37","first-page":"310","volume":"70","author":"SH Zhang","year":"2018","unstructured":"Zhang SH, Du YH, Yu HC, Li YM, Liu HR. Research advances in the regulation of cardiovascular metabolic disorders and its related risk factors by C1q\/TNF related proteins. Sheng Li Xue Bao. 2018;70(3):310\u20138.","journal-title":"Sheng Li Xue Bao"},{"issue":"11","key":"385_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2165\/00023210-200115110-00004","volume":"15","author":"S Lacour","year":"2001","unstructured":"Lacour S. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs. 2001;15(11):853\u201370.","journal-title":"CNS Drugs"},{"issue":"1\u20132","key":"385_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11010-015-2531-y","volume":"409","author":"F Otani","year":"2015","unstructured":"Otani F, Wakisaka M. A novel adipokine C1q\/TNF-related protein 3 is expressed in developing skeletal muscle and controls myoblast proliferation and differentiation. Mol Cell Biochem. 2015;409(1\u20132):271\u201382.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"385_CR40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0963689718822809","volume":"28","author":"L Zhao","year":"2019","unstructured":"Zhao L, Zhang JH, Sherchan P, Krafft PR, Zhao W, Wang S, Chen S, Guo Z, Tang J. Administration of rCTRP9 attenuates neuronal apoptosis through AdipoR1\/PI3K\/Akt signaling pathway after ICH in mice. Cell Transplant. 2019;28(6):756\u201366.","journal-title":"Cell Transplant"},{"issue":"13","key":"385_CR41","doi-asserted-by":"publisher","first-page":"10301","DOI":"10.1074\/jbc.M111.303651","volume":"287","author":"Z Wei","year":"2012","unstructured":"Wei Z, Peterson JM, Lei X, Cebotaru L, Wolfgang MJ, Baldeviano GC, Wong GW. C1q\/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem. 2012;287(13):10301\u201315.","journal-title":"J Biol Chem"},{"issue":"2","key":"385_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11154-013-9255-7","volume":"15","author":"MM Seldin","year":"2013","unstructured":"Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord. 2013;15(2):111\u201323.","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-022-00385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-022-00385-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-022-00385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:11:16Z","timestamp":1649081476000},"score":1,"resource":{"primary":{"URL":"https:\/\/biolres.biomedcentral.com\/articles\/10.1186\/s40659-022-00385-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s40659-022-00385-3","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the second affiliated hospital of air force medical university and adhered to the ethical guidelines of the Declaration of Helsinki. All patients and healthy volunteers gave their informed consent to the study and signed the informed consent form. All methods were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no competing interest to be declared by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}